BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 19525448)

  • 21. Use of a single hybrid imaging agent for integration of target validation with in vivo and ex vivo imaging of mouse tumor lesions resembling human DCIS.
    Buckle T; Kuil J; van den Berg NS; Bunschoten A; Lamb HJ; Yuan H; Josephson L; Jonkers J; Borowsky AD; van Leeuwen FW
    PLoS One; 2013; 8(1):e48324. PubMed ID: 23326303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo biodistribution, PET imaging, and tumor accumulation of 86Y- and 111In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice.
    Schneider DW; Heitner T; Alicke B; Light DR; McLean K; Satozawa N; Parry G; Yoo J; Lewis JS; Parry R
    J Nucl Med; 2009 Mar; 50(3):435-43. PubMed ID: 19223400
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
    McLarty K; Cornelissen B; Cai Z; Scollard DA; Costantini DL; Done SJ; Reilly RM
    J Nucl Med; 2009 Aug; 50(8):1340-8. PubMed ID: 19617342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [⁹⁹mTc]O₂-AMD3100 as a SPECT tracer for CXCR4 receptor imaging.
    Hartimath SV; Domanska UM; Walenkamp AM; Rudi A J O D; de Vries EF
    Nucl Med Biol; 2013 May; 40(4):507-17. PubMed ID: 23522974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitation of CXCR4 expression in myocardial infarction using 99mTc-labeled SDF-1alpha.
    Misra P; Lebeche D; Ly H; Schwarzkopf M; Diaz G; Hajjar RJ; Schecter AD; Frangioni JV
    J Nucl Med; 2008 Jun; 49(6):963-9. PubMed ID: 18483105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SPECT imaging of colorectal cancer by targeting CD 133 receptor with 99mTc-labeled monoclonal antibody.
    Liu Y; Jin X; Lan X; Lang J; Wen Q; An R
    Q J Nucl Med Mol Imaging; 2019 Jun; 63(2):216-224. PubMed ID: 27387378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of
    Banerjee SR; Kumar V; Lisok A; Plyku D; Nováková Z; Brummet M; Wharram B; Barinka C; Hobbs R; Pomper MG
    J Nucl Med; 2019 Mar; 60(3):400-406. PubMed ID: 30237212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of Tryptophan Uptake and Kinetics Using 1-(2-18F-Fluoroethyl)-l-Tryptophan and α-11C-Methyl-l-Tryptophan PET Imaging in Mice Implanted with Patient-Derived Brain Tumor Xenografts.
    Michelhaugh SK; Muzik O; Guastella AR; Klinger NV; Polin LA; Cai H; Xin Y; Mangner TJ; Zhang S; Juhász C; Mittal S
    J Nucl Med; 2017 Feb; 58(2):208-213. PubMed ID: 27765857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
    Ahlgren S; Wållberg H; Tran TA; Widström C; Hjertman M; Abrahmsén L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V
    J Nucl Med; 2009 May; 50(5):781-9. PubMed ID: 19372467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.
    Elsässer-Beile U; Reischl G; Wiehr S; Bühler P; Wolf P; Alt K; Shively J; Judenhofer MS; Machulla HJ; Pichler BJ
    J Nucl Med; 2009 Apr; 50(4):606-11. PubMed ID: 19289418
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and Evaluation of an
    Brickute D; Braga M; Kaliszczak MA; Barnes C; Lau D; Carroll L; Stevens E; Trousil S; Alam IS; Nguyen QD; Aboagye EO
    Mol Pharm; 2019 May; 16(5):2106-2117. PubMed ID: 30883140
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting primary human Ph(+) B-cell precursor leukemia-engrafted SCID mice using radiolabeled anti-CD19 monoclonal antibodies.
    Mitchell P; Lee FT; Hall C; Rigopoulos A; Smyth FE; Hekman AM; van Schijndel GM; Powles R; Brechbiel MW; Scott AM
    J Nucl Med; 2003 Jul; 44(7):1105-12. PubMed ID: 12843229
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors.
    Hanaoka H; Mukai T; Tamamura H; Mori T; Ishino S; Ogawa K; Iida Y; Doi R; Fujii N; Saji H
    Nucl Med Biol; 2006 May; 33(4):489-94. PubMed ID: 16720240
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imaging CXCR4 Expression with (99m)Tc-Radiolabeled Small-Interference RNA in Experimental Human Breast Cancer Xenografts.
    Fu P; Tian L; Cao X; Li L; Xu P; Zhao C
    Mol Imaging Biol; 2016 Jun; 18(3):353-9. PubMed ID: 26452556
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-Contrast CXCR4-Targeted
    Kwon D; Lozada J; Zhang Z; Zeisler J; Poon R; Zhang C; Roxin Á; Lin KS; Perrin D; Benard F
    Mol Pharm; 2021 Jan; 18(1):187-197. PubMed ID: 33253591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Locoregional Confinement and Major Clinical Benefit of
    Séhédic D; Chourpa I; Tétaud C; Griveau A; Loussouarn C; Avril S; Legendre C; Lepareur N; Wion D; Hindré F; Davodeau F; Garcion E
    Theranostics; 2017; 7(18):4517-4536. PubMed ID: 29158842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Activation of CXCR4 in human glioma stem cells promotes tumor angiogenesis].
    Ping YF; Yao XH; Bian XW; Chen JH; Zhang R; Yi L; Zhou ZH
    Zhonghua Bing Li Xue Za Zhi; 2007 Mar; 36(3):179-83. PubMed ID: 17535685
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model.
    Mercurio L; Ajmone-Cat MA; Cecchetti S; Ricci A; Bozzuto G; Molinari A; Manni I; Pollo B; Scala S; Carpinelli G; Minghetti L
    J Exp Clin Cancer Res; 2016 Mar; 35():55. PubMed ID: 27015814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [
    Amor-Coarasa A; Kelly J; Ponnala S; Vedvyas Y; Nikolopoulou A; Williams C; Jin MM; David Warren J; Babich JW
    Nucl Med Biol; 2018 May; 60():37-44. PubMed ID: 29544122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of [125I]IPOS as a molecular imaging probe for hypoxia-inducible factor-1-active regions in a tumor: comparison among single-photon emission computed tomography/X-ray computed tomography imaging, autoradiography, and immunohistochemistry.
    Ueda M; Kudo T; Mutou Y; Umeda IO; Miyano A; Ogawa K; Ono M; Fujii H; Kizaka-Kondoh S; Hiraoka M; Saji H
    Cancer Sci; 2011 Nov; 102(11):2090-6. PubMed ID: 21824221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.